These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 25135990)

  • 1. Calcium/magnesium infusion for oxaliplatin-induced neuropathy: protective or not?
    Avan A; Avan A; Giovannetti E; Peters GJ
    J Clin Oncol; 2014 Oct; 32(29):3341. PubMed ID: 25135990
    [No Abstract]   [Full Text] [Related]  

  • 2. Estimating the value of intravenous calcium and magnesium in ameliorating oxaliplatin-induced neuropathy.
    Atkins CD
    J Clin Oncol; 2014 Oct; 32(29):3341. PubMed ID: 25135996
    [No Abstract]   [Full Text] [Related]  

  • 3. Reply to C.d. Atkins and a. Avan et Al.
    Loprinzi CL; Qin R; Grothey A
    J Clin Oncol; 2014 Oct; 32(29):3342-3. PubMed ID: 25135995
    [No Abstract]   [Full Text] [Related]  

  • 4. Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance).
    Loprinzi CL; Qin R; Dakhil SR; Fehrenbacher L; Flynn KA; Atherton P; Seisler D; Qamar R; Lewis GC; Grothey A
    J Clin Oncol; 2014 Apr; 32(10):997-1005. PubMed ID: 24297951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calcium and magnesium for oxaliplatin-induced neuropathy.
    Stansfield L
    Am J Health Syst Pharm; 2014 Jun; 71(12):987-8. PubMed ID: 24865753
    [No Abstract]   [Full Text] [Related]  

  • 6. Calcium and Magnesium Use for Oxaliplatin-Induced Neuropathy: A Case Study to Assess How Quickly Evidence Translates Into Practice.
    Pachman DR; Ruddy K; Sangaralingham LR; Grothey A; Shah ND; Beutler AS; Hubbard JM; Loprinzi CL
    J Natl Compr Canc Netw; 2015 Sep; 13(9):1097-101. PubMed ID: 26358793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance).
    Pachman DR; Qin R; Seisler DK; Smith EM; Beutler AS; Ta LE; Lafky JM; Wagner-Johnston ND; Ruddy KJ; Dakhil S; Staff NP; Grothey A; Loprinzi CL
    J Clin Oncol; 2015 Oct; 33(30):3416-22. PubMed ID: 26282635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recurrent priapism related to oxaliplatin infusion.
    Adenis A; Mailliez A; Rigot JM; Gamelin L; Vanhuyse M; Gamelin E
    J Clin Oncol; 2008 Feb; 26(6):1016-7. PubMed ID: 18281680
    [No Abstract]   [Full Text] [Related]  

  • 9. Xaliproden lessens oxaliplatin-mediated neuropathy.
    Susman E
    Lancet Oncol; 2006 Apr; 7(4):288. PubMed ID: 16598880
    [No Abstract]   [Full Text] [Related]  

  • 10. [Reduction of oxaliplatin-related neurotoxicity by calcium and magnesium infusions].
    Muto O; Ando H; Ono T; Itagaki H; Kobayashi Y; Onuki M; Akashi T; Tanaka Y; Hanaoka T
    Gan To Kagaku Ryoho; 2007 Apr; 34(4):579-81. PubMed ID: 17431344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preventing oxaliplatin-induced sensory neurotoxicity: a methodology perspective.
    Chan A; Chiang J; Lew KY; Chay WY
    J Clin Oncol; 2011 Jun; 29(16):e489; author reply e490-1. PubMed ID: 21482983
    [No Abstract]   [Full Text] [Related]  

  • 12. Safety and efficacy of calcium and magnesium infusions in the chemoprevention of oxaliplatin-induced sensory neuropathy in gastrointestinal cancers.
    Xu XT; Dai ZH; Xu Q; Qiao YQ; Gu Y; Nie F; Zhu MM; Tong JL; Ran ZH
    J Dig Dis; 2013 Jun; 14(6):288-98. PubMed ID: 23432969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Genetic backgrounds of peripheral neuropathy induced by oxaliplatin].
    Mitsuma A; Ando Y
    Nihon Yakurigaku Zasshi; 2013 Feb; 141(2):62-5. PubMed ID: 23391543
    [No Abstract]   [Full Text] [Related]  

  • 14. Peripheral sensory neuropathy--fighting cold with cold.
    Castro M
    Lancet Oncol; 2008 May; 9(5):415-6. PubMed ID: 18452855
    [No Abstract]   [Full Text] [Related]  

  • 15. Calcium channel blockers reduce oxaliplatin-induced acute neuropathy: a retrospective study of 69 male patients receiving modified FOLFOX6 therapy.
    Tatsushima Y; Egashira N; Narishige Y; Fukui S; Kawashiri T; Yamauchi Y; Oishi R
    Biomed Pharmacother; 2013 Feb; 67(1):39-42. PubMed ID: 23206755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New data question treatment for oxaliplatin neurotoxicity.
    Wolf SL
    Clin J Oncol Nurs; 2008 Feb; 12(1):14; author reply 14. PubMed ID: 18323035
    [No Abstract]   [Full Text] [Related]  

  • 17. Oxaliplatin-mediated autoimmune thrombocytopenia.
    Saif MW; The A; Ledbetter L
    Clin Colorectal Cancer; 2009 Jan; 8(1):61-2. PubMed ID: 19203900
    [No Abstract]   [Full Text] [Related]  

  • 18. Calcium and magnesium prophylaxis for oxaliplatin-related neurotoxicity: is it a trade-off between drug efficacy and toxicity?
    Khattak MA
    Oncologist; 2011; 16(12):1780-3. PubMed ID: 22128115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prevention of oxaliplatin-induced neuropathy by carbamazepine. A pilot study].
    Eckel F; Schmelz R; Adelsberger H; Erdmann J; Quasthoff S; Lersch C
    Dtsch Med Wochenschr; 2002 Jan; 127(3):78-82. PubMed ID: 11797144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calcium and magnesium prophylaxis for oxaliplatin-related neurotoxicity: is it a trade-off between drug efficacy and toxicity?
    Cavaletti G
    Oncologist; 2011; 16(12):1667-8. PubMed ID: 22128117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.